The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer
Autor(a) principal: | |
---|---|
Data de Publicação: | 2024 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Brazilian Journal of Health Review |
Texto Completo: | https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/67502 |
Resumo: | Introduction: Gastric cancer is a chronic non-communicable disease that is increasingly recurring around the world. Based on this theme, we know the importance of adequate treatment to avoid negative repercussions on health. Therefore, it is necessary to identify the PPIs most used as an adjunct in the treatment of potential gastric lesions for the development of neoplasia. Material and methods: This is an integrative review of the literature on the therapeutic use of proton pump inhibitors associated with the development of gastric cancer. To problematize the research, the following guiding question was used: What are the PPIs most used as an adjunct in the treatment of gastric lesions that are potential for the development of gastric cancer? The database provided by (PUBMED) was used for research. To correctly search for terms, the key words were checked in DeCS. Results: The main antibiotics identified were: amoxicillin, clarithromycin and tetracillin, and the main PPIs: Omeprazole, vanoprazole, rabeprazole, metronidazole and lansoprazole. The antibiotic, amoxicillin, and the PPIs omeprazole, were the most common medications in the study. However, with different associations. The duration of use of the drug combinations ranged from 10 days to 4 weeks, however, most articles showed a relationship with the eradication of the bacteria after using the drug combination. Conclusion: The antibiotic, amoxicillin, and the PPIs, omeprazole, were the most common medications in the study. However, with different combinations. Therefore, it can be concluded that there is no standardized treatment to reduce potential lesions for the development of gastric neoplasms. Therefore, it is worth highlighting the importance of more studies that can address this issue that has a major impact on public health. |
id |
BJRH-0_e337a63f7e0095f93c16ca419a7ca233 |
---|---|
oai_identifier_str |
oai:ojs2.ojs.brazilianjournals.com.br:article/67502 |
network_acronym_str |
BJRH-0 |
network_name_str |
Brazilian Journal of Health Review |
repository_id_str |
|
spelling |
The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancerdrug therapystomach neoplasmsproton pump inhibitorsIntroduction: Gastric cancer is a chronic non-communicable disease that is increasingly recurring around the world. Based on this theme, we know the importance of adequate treatment to avoid negative repercussions on health. Therefore, it is necessary to identify the PPIs most used as an adjunct in the treatment of potential gastric lesions for the development of neoplasia. Material and methods: This is an integrative review of the literature on the therapeutic use of proton pump inhibitors associated with the development of gastric cancer. To problematize the research, the following guiding question was used: What are the PPIs most used as an adjunct in the treatment of gastric lesions that are potential for the development of gastric cancer? The database provided by (PUBMED) was used for research. To correctly search for terms, the key words were checked in DeCS. Results: The main antibiotics identified were: amoxicillin, clarithromycin and tetracillin, and the main PPIs: Omeprazole, vanoprazole, rabeprazole, metronidazole and lansoprazole. The antibiotic, amoxicillin, and the PPIs omeprazole, were the most common medications in the study. However, with different associations. The duration of use of the drug combinations ranged from 10 days to 4 weeks, however, most articles showed a relationship with the eradication of the bacteria after using the drug combination. Conclusion: The antibiotic, amoxicillin, and the PPIs, omeprazole, were the most common medications in the study. However, with different combinations. Therefore, it can be concluded that there is no standardized treatment to reduce potential lesions for the development of gastric neoplasms. Therefore, it is worth highlighting the importance of more studies that can address this issue that has a major impact on public health.Brazilian Journals Publicações de Periódicos e Editora Ltda.2024-02-23info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/6750210.34119/bjhrv7n1-556Brazilian Journal of Health Review; Vol. 7 No. 1 (2024); 6833-6844Brazilian Journal of Health Review; Vol. 7 Núm. 1 (2024); 6833-6844Brazilian Journal of Health Review; v. 7 n. 1 (2024); 6833-68442595-6825reponame:Brazilian Journal of Health Reviewinstname:Federação das Indústrias do Estado do Paraná (FIEP)instacron:BJRHporhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/67502/48063Guimarães, Júlia Silva JaymeGomes, Maria Clara TassaraMoura, Bianca DubbersteinSilva, Patrícia NavesGomes, João Paulo TeixeiraVian, Marcela AndradeLeão, Marina CabralSoave, Danilo Figueiredoinfo:eu-repo/semantics/openAccess2024-02-27T14:30:14Zoai:ojs2.ojs.brazilianjournals.com.br:article/67502Revistahttp://www.brazilianjournals.com/index.php/BJHR/indexPRIhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/oai|| brazilianjhr@gmail.com2595-68252595-6825opendoar:2024-02-27T14:30:14Brazilian Journal of Health Review - Federação das Indústrias do Estado do Paraná (FIEP)false |
dc.title.none.fl_str_mv |
The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer |
title |
The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer |
spellingShingle |
The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer Guimarães, Júlia Silva Jayme drug therapy stomach neoplasms proton pump inhibitors |
title_short |
The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer |
title_full |
The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer |
title_fullStr |
The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer |
title_full_unstemmed |
The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer |
title_sort |
The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer |
author |
Guimarães, Júlia Silva Jayme |
author_facet |
Guimarães, Júlia Silva Jayme Gomes, Maria Clara Tassara Moura, Bianca Dubberstein Silva, Patrícia Naves Gomes, João Paulo Teixeira Vian, Marcela Andrade Leão, Marina Cabral Soave, Danilo Figueiredo |
author_role |
author |
author2 |
Gomes, Maria Clara Tassara Moura, Bianca Dubberstein Silva, Patrícia Naves Gomes, João Paulo Teixeira Vian, Marcela Andrade Leão, Marina Cabral Soave, Danilo Figueiredo |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Guimarães, Júlia Silva Jayme Gomes, Maria Clara Tassara Moura, Bianca Dubberstein Silva, Patrícia Naves Gomes, João Paulo Teixeira Vian, Marcela Andrade Leão, Marina Cabral Soave, Danilo Figueiredo |
dc.subject.por.fl_str_mv |
drug therapy stomach neoplasms proton pump inhibitors |
topic |
drug therapy stomach neoplasms proton pump inhibitors |
description |
Introduction: Gastric cancer is a chronic non-communicable disease that is increasingly recurring around the world. Based on this theme, we know the importance of adequate treatment to avoid negative repercussions on health. Therefore, it is necessary to identify the PPIs most used as an adjunct in the treatment of potential gastric lesions for the development of neoplasia. Material and methods: This is an integrative review of the literature on the therapeutic use of proton pump inhibitors associated with the development of gastric cancer. To problematize the research, the following guiding question was used: What are the PPIs most used as an adjunct in the treatment of gastric lesions that are potential for the development of gastric cancer? The database provided by (PUBMED) was used for research. To correctly search for terms, the key words were checked in DeCS. Results: The main antibiotics identified were: amoxicillin, clarithromycin and tetracillin, and the main PPIs: Omeprazole, vanoprazole, rabeprazole, metronidazole and lansoprazole. The antibiotic, amoxicillin, and the PPIs omeprazole, were the most common medications in the study. However, with different associations. The duration of use of the drug combinations ranged from 10 days to 4 weeks, however, most articles showed a relationship with the eradication of the bacteria after using the drug combination. Conclusion: The antibiotic, amoxicillin, and the PPIs, omeprazole, were the most common medications in the study. However, with different combinations. Therefore, it can be concluded that there is no standardized treatment to reduce potential lesions for the development of gastric neoplasms. Therefore, it is worth highlighting the importance of more studies that can address this issue that has a major impact on public health. |
publishDate |
2024 |
dc.date.none.fl_str_mv |
2024-02-23 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/67502 10.34119/bjhrv7n1-556 |
url |
https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/67502 |
identifier_str_mv |
10.34119/bjhrv7n1-556 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/67502/48063 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Brazilian Journals Publicações de Periódicos e Editora Ltda. |
publisher.none.fl_str_mv |
Brazilian Journals Publicações de Periódicos e Editora Ltda. |
dc.source.none.fl_str_mv |
Brazilian Journal of Health Review; Vol. 7 No. 1 (2024); 6833-6844 Brazilian Journal of Health Review; Vol. 7 Núm. 1 (2024); 6833-6844 Brazilian Journal of Health Review; v. 7 n. 1 (2024); 6833-6844 2595-6825 reponame:Brazilian Journal of Health Review instname:Federação das Indústrias do Estado do Paraná (FIEP) instacron:BJRH |
instname_str |
Federação das Indústrias do Estado do Paraná (FIEP) |
instacron_str |
BJRH |
institution |
BJRH |
reponame_str |
Brazilian Journal of Health Review |
collection |
Brazilian Journal of Health Review |
repository.name.fl_str_mv |
Brazilian Journal of Health Review - Federação das Indústrias do Estado do Paraná (FIEP) |
repository.mail.fl_str_mv |
|| brazilianjhr@gmail.com |
_version_ |
1797240043058757632 |